Jula Inrig, Travere R&D EVP, sells $2.78m in shares
Jula Inrig, Executive Vice President, Head of Research & Development and Chief Medical Officer at Travere Therapeutics, Inc. (TVTX), sold 44,674 shares of common stock on September 15, 2026, for $2,785,020. The sale occurred at prices ranging from $62.0167 to $65.31. Before selling, Inrig acquired 32,395 shares by exercising employee stock options at $8.93 per share.
These sales were executed according to a Rule 10b5-1 trading plan adopted on June 16, 2026. The transactions comprised various portions: 25,390 shares at an average price of $62.0167, 17,284 shares at $62.6242, 1,600 shares at $63.685, and 400 shares at $65.31. Following these sales, Inrig beneficially owns 100,491 shares of Travere Therapeutics common stock.
Travere Therapeutics reported a Q2 revenue of $169.6 million, exceeding expectations of $160.66 million. This increase was primarily due to a 96% sales rise for their kidney drug FILSPARI, which generated $141.1 million in revenue. The company also earned $8.2 million from licensing and collaboration agreements. Stifel raised its price target for Travere Therapeutics to $62, maintaining a Hold rating.
The company concluded the quarter with $489.2 million in cash, equivalents, and marketable securities.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
